On May 11, 2022 Amber Specialty Pharmacy reported that they will begin dispensing LENVIMA (lenvatinib). Used by itself, LENVIMA treats differentiated thyroid cancer (DTC) when it can no longer be treated with radioactive iodine, and hepatocellular carcinoma (HCC) when it cannot be removed by surgery (Press release, Amber Specialty Pharmacy, MAY 11, 2022, View Source [SID1234614245]). LENVIMA is used with other medications to treat additional types of cancers, including advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma. LENVIMA is manufactured by Eisai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amber Specialty Pharmacy’s high-touch service model will support patients, caregivers, and oncology specialists throughout the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.

"Supporting patients who are navigating a cancer diagnosis is one of the most important things we do," said Kristin Williams, president of Amber Specialty Pharmacy. "We are honored Eisai recognizes the value our whole-health approach offers oncology patients. From reducing or eliminating financial barriers, to one-on-one counseling with our registered dietitian – and everything in between – oncology professionals can trust Amber Specialty Pharmacy to make sure patients have the medicine and support they deserve."